Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Stock Information for Anixa Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Anixa Biosciences Inc.

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.